Kennedy Capital Management LLC Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Kennedy Capital Management LLC lowered its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 2.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,017,666 shares of the biopharmaceutical company’s stock after selling 23,750 shares during the period. Kennedy Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $21,239,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. JPMorgan Chase & Co. raised its holdings in Catalyst Pharmaceuticals by 9.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after purchasing an additional 33,888 shares during the period. Farther Finance Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Catalyst Pharmaceuticals by 13.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company’s stock valued at $8,710,000 after purchasing an additional 50,888 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $1,185,000. Finally, Redhawk Wealth Advisors Inc. acquired a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $1,273,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now directly owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Analyst Upgrades and Downgrades

CPRX has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Bank of America reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Stephens reissued an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Finally, Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX opened at $22.74 on Thursday. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 3.31 and a beta of 0.79. The company has a 50-day moving average of $22.68 and a two-hundred day moving average of $21.98. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.